Roche said last week that the Cobas TaqScreen DPX test for use on the Cobas S 201 system is now available in the US.

Cobas TaqScreen DPX is the first commercial test to quantify parvovirus B19 and detect hepatitis A virus simultaneously in one assay in human plasma, Roche said.

Both parvovirus B19 and HAV are difficult to inactivate by traditional methods used by the plasma industry, and there have been reports on the transmission of the viruses through blood and plasma products, Roche said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.